Annual Accounts Payable
$13.81 M
+$9.26 M+203.76%
December 31, 2023
Summary
- As of February 7, 2025, RVNC annual accounts payable is $13.81 million, with the most recent change of +$9.26 million (+203.76%) on December 31, 2023.
- During the last 3 years, RVNC annual accounts payable has risen by +$1.15 million (+9.10%).
- RVNC annual accounts payable is now at all-time high.
Performance
RVNC Accounts Payable Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly Accounts Payable
$12.34 M
+$7.35 M+147.44%
September 30, 2024
Summary
- As of February 7, 2025, RVNC quarterly accounts payable is $12.34 million, with the most recent change of +$7.35 million (+147.44%) on September 30, 2024.
- Over the past year, RVNC quarterly accounts payable has increased by +$7.56 million (+158.32%).
- RVNC quarterly accounts payable is now -10.67% below its all-time high of $13.81 million, reached on December 31, 2023.
Performance
RVNC Quarterly Accounts Payable Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Accounts Payable Formula
Accounts Payable = Beginning Accounts Payable + Purchases on Credit − Payments to Suppliers
RVNC Accounts Payable Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | +203.8% | +158.3% |
| 3 y3 years | +9.1% | +53.5% |
| 5 y5 years | +63.7% | +78.7% |
RVNC Accounts Payable Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3-year | at high | +203.8% | -10.7% | +1557.9% |
| 5 y | 5-year | at high | +203.8% | -10.7% | +1557.9% |
| alltime | all time | at high | +1677.2% | -10.7% | +1557.9% |
Revance Therapeutics Accounts Payable History
| Date | Annual | Quarterly |
|---|---|---|
| Sep 2024 | - | $12.34 M(+147.4%) |
| Jun 2024 | - | $4.99 M(-5.5%) |
| Mar 2024 | - | $5.28 M(-61.8%) |
| Dec 2023 | $13.81 M(+203.8%) | $13.81 M(+189.2%) |
| Sep 2023 | - | $4.78 M(-42.8%) |
| Jun 2023 | - | $8.35 M(-35.8%) |
| Mar 2023 | - | $13.00 M(+185.9%) |
| Dec 2022 | $4.55 M(-57.1%) | $4.55 M(+511.0%) |
| Sep 2022 | - | $744.00 K(-94.4%) |
| Jun 2022 | - | $13.27 M(+32.5%) |
| Mar 2022 | - | $10.02 M(-5.5%) |
| Dec 2021 | $10.60 M(-16.2%) | $10.60 M(+31.9%) |
| Sep 2021 | - | $8.04 M(-1.7%) |
| Jun 2021 | - | $8.18 M(+15.5%) |
| Mar 2021 | - | $7.08 M(-44.1%) |
| Dec 2020 | $12.66 M(+58.0%) | $12.66 M(+61.0%) |
| Sep 2020 | - | $7.86 M(+19.0%) |
| Jun 2020 | - | $6.60 M(-24.2%) |
| Mar 2020 | - | $8.71 M(+8.7%) |
| Dec 2019 | $8.01 M(-5.0%) | $8.01 M(+16.1%) |
| Sep 2019 | - | $6.90 M(-13.4%) |
| Jun 2019 | - | $7.97 M(+77.6%) |
| Mar 2019 | - | $4.49 M(-46.8%) |
| Date | Annual | Quarterly |
|---|---|---|
| Dec 2018 | $8.43 M(+23.9%) | $8.43 M(+14.9%) |
| Sep 2018 | - | $7.34 M(+35.1%) |
| Jun 2018 | - | $5.43 M(+1.4%) |
| Mar 2018 | - | $5.36 M(-21.2%) |
| Dec 2017 | $6.80 M(+81.3%) | $6.80 M(+1.9%) |
| Sep 2017 | - | $6.68 M(+63.8%) |
| Jun 2017 | - | $4.08 M(-26.8%) |
| Mar 2017 | - | $5.57 M(+48.5%) |
| Dec 2016 | $3.75 M(+41.3%) | $3.75 M(+30.8%) |
| Sep 2016 | - | $2.87 M(-3.7%) |
| Jun 2016 | - | $2.98 M(-9.8%) |
| Mar 2016 | - | $3.31 M(+24.5%) |
| Dec 2015 | $2.66 M(-15.6%) | $2.66 M(-2.7%) |
| Sep 2015 | - | $2.73 M(+23.5%) |
| Jun 2015 | - | $2.21 M(+5.8%) |
| Mar 2015 | - | $2.09 M(-33.7%) |
| Dec 2014 | $3.15 M(-43.0%) | $3.15 M(+18.1%) |
| Sep 2014 | - | $2.67 M(-0.8%) |
| Jun 2014 | - | $2.69 M(-27.2%) |
| Mar 2014 | - | $3.69 M(-33.2%) |
| Dec 2013 | $5.53 M(+206.1%) | $5.53 M(-45.0%) |
| Sep 2013 | - | $10.05 M(+457.0%) |
| Dec 2012 | $1.80 M(+132.3%) | $1.80 M |
| Dec 2011 | $777.00 K | - |
FAQ
- What is Revance Therapeutics annual accounts payable?
- What is the all time high annual accounts payable for Revance Therapeutics?
- What is Revance Therapeutics annual accounts payable year-on-year change?
- What is Revance Therapeutics quarterly accounts payable?
- What is the all time high quarterly accounts payable for Revance Therapeutics?
- What is Revance Therapeutics quarterly accounts payable year-on-year change?
What is Revance Therapeutics annual accounts payable?
The current annual accounts payable of RVNC is $13.81 M
What is the all time high annual accounts payable for Revance Therapeutics?
Revance Therapeutics all-time high annual accounts payable is $13.81 M
What is Revance Therapeutics annual accounts payable year-on-year change?
Over the past year, RVNC annual accounts payable has changed by +$9.26 M (+203.76%)
What is Revance Therapeutics quarterly accounts payable?
The current quarterly accounts payable of RVNC is $12.34 M
What is the all time high quarterly accounts payable for Revance Therapeutics?
Revance Therapeutics all-time high quarterly accounts payable is $13.81 M
What is Revance Therapeutics quarterly accounts payable year-on-year change?
Over the past year, RVNC quarterly accounts payable has changed by +$7.56 M (+158.32%)